

News Releases

All Years



Search

GO

[Advanced Search](#)

Sep 11, 2018

U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals' Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process

Action Date Set for December 31, 2018

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged...

Sep 7, 2018

Portola Pharmaceuticals Announces Executive Leadership Change

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that Tao Fu, chief commercial officer, has resigned effective...

Sep 5, 2018

Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) announced today that on August 31, 2018, the Compensation Committee of the Board of...

Aug 31, 2018

Portola Pharmaceuticals Submits Prior Approval Supplement to U.S. FDA for Large-Scale Generation 2 Andexxa Process

SOUTH SAN FRANCISCO, Calif., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the submission of a prior approval supplement (PAS) to the U.S. Food...

Aug 30, 2018

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced that the company will participate in the following conferences in...

Show 5 per page

[<](#) [1](#) ... [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) ... [50](#) [>](#)



<https://investors.portola.com/news-releases?o=45>